SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000891293-22-000015
Filing Date
2022-04-19
Accepted
2022-04-19 17:19:07
Documents
5
Period of Report
2022-06-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A ctic-2022proxystatementdef.htm DEF 14A 740238
2 acraignsignaturea06.jpg GRAPHIC 8270
3 cti_logoxrgbx1501002.jpg GRAPHIC 25747
4 ctiproxycardback.jpg GRAPHIC 142286
5 ctiproxycardfront.jpg GRAPHIC 129422
  Complete submission text file 0000891293-22-000015.txt   1161348
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-28386 | Film No.: 22835654
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences